DataMEDS AI to acquire Todos Medical's TBIA cancer blood test platform
What's the deal? DataMEDS AIDealroom has a profile for this one. Try Dealroom → has agreed to acquire TBIA, a cancer-detection AI blood test platform, from the estate of Todos MedicalDealroom has a profile for this one. Try Dealroom →. The deal, announced in November 2026, will be carried out through DataMEDS AI subsidiary Helomics, Inc. Terms were not disclosed.
What each side brings: DataMEDS AI runs a CLIA-certified cancer diagnostics laboratory. TBIA is built around a spectroscopy platform that analyses blood to detect cancer.
What's the endgame? DataMEDS AI plans to use TBIA's spectroscopy technology to expand its machine learning into additional cancer types. The acquisition folds the platform into Helomics' diagnostics operations.
The signal: Buying a diagnostics platform out of a company estate gives DataMEDS AI an established technology base without building one from scratch — a lower-cost route to widening its cancer-detection menu.
Read more: article.wn.com
Image credit: Generated with Gemini